The KRAS Drug Development Landscape Report
Mutations in KRAS are among the most common oncogenic drivers in cancer. KRAS was once considered “undruggable” but recent breakthroughs have enabled the development of targeted therapies for the treatment of oncology indications.
This Report Offers Insight Into:
- Comprehensive review of KRAS-targeted therapies: including recent drug approvals, pipeline advancements, and therapeutic class analysis
- In-depth analysis of the KRAS clinical trial landscape: spotlighting annual growth trends, disease indications, and standout investigational assets
- Insightful overview of the 2025 KRAS deal landscape: detailing major transactions, strategic partnerships, and projected deal valuations
- Key highlights from the World Conference on Lung Cancer: featuring summaries of KRAS-related preclinical and clinical abstracts
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
